학술논문

262P Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis
Document Type
Abstract
Source
In Annals of Oncology September 2022 33 Supplement 7:S657-S657
Subject
Language
ISSN
0923-7534